Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial - Archive ouverte HAL Access content directly
Journal Articles Journal of Neurology Year : 2023

Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial

Noémie Timestit
  • Function : Author
Ana Marques
  • Function : Author
Domitille Dilly Duchez
  • Function : Author
Caroline Giordana
  • Function : Author
Sara Meoni
  • Function : Author
Tiphaine Vidal
  • Function : Author
Marion Fatisson
  • Function : Author
Mikail Nourredine
Sylvie Bin
  • Function : Author

Abstract

Background Impulse control disorders (ICDs) are frequently encountered in Parkinson's disease (PD). Objectives We aimed to assess whether clonidine, an α2-adrenergic receptor agonist, would improve ICDs. Methods We conducted a multicentre trial in five movement disorder departments. Patients with PD and ICDs (n = 41) were enrolled in an 8-week, randomised (1:1), double-blind, placebo-controlled study of clonidine (75 μg twice a day). Randomisation and allocation to the trial group were carried out by a central computer system. The primary outcome was the change at 8 weeks in symptom severity using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) score. A reduction of the most elevated subscore of the QUIP-RS of more than 3 points without any increase in the other QUIP-RS dimension defined success. Results Between 15 May 2019 and 10 September 2021, 19 patients in the clonidine group and 20 patients in the placebo group were enrolled. The proportion difference of success in reducing QUIP-RS at 8 weeks, was 7% (one-sided upper 90% CI 27%) with 42.1% of success in the clonidine group and 35.0% in the placebo group. Compared to patients in the placebo group, patients in the clonidine group experienced a greater reduction in the total QUIP-RS score at 8 weeks (11.0 points vs. 3.6). Discussion Clonidine was well tolerated but our study was not enough powerful to demonstrate significant superiority compared to placebo in reducing ICDs despite a greater reduction of total QUIP score at 8 weeks. A phase 3 study should be conducted. Trial Registration The study was registered (NCT03552068) on clinicaltrials.gov on June 11, 2018.
Fichier principal
Vignette du fichier
Laurencin et al. - 2023 - Efficacy and safety of clonidine for the treatment.pdf (762.3 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-04274916 , version 1 (08-11-2023)

Identifiers

Cite

Chloé Laurencin, Noémie Timestit, Ana Marques, Domitille Dilly Duchez, Caroline Giordana, et al.. Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial. Journal of Neurology, 2023, 270, pp.4851 - 4859. ⟨10.1007/s00415-023-11814-y⟩. ⟨hal-04274916⟩
22 View
11 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More